Research programme: proteasome inhibitors - Cytomics Systems

Drug Profile

Research programme: proteasome inhibitors - Cytomics Systems

Alternative Names: NOPPI; REACTA

Latest Information Update: 07 Jan 2011

Price : $50

At a glance

  • Originator Cytomics Systems
  • Class Small molecules
  • Mechanism of Action Apoptosis stimulants; Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 07 Jan 2011 Preclinical development is ongoing in France
  • 05 Aug 2005 Preclinical trials in Cancer in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top